Clinical Trials for Amyloidosis Patients - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Clinical Trials for Amyloidosis Patients

Clinical Trials for Amyloidosis Patients image

Clinical Trials for Amyloidosis Patients

Webinar
event Oct 18, 2022 / 01:00PM - 02:00PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Join Dr. Heather Landau as she shares potential clinical trials for amyloidosis patients who might be looking to advance research in the amyloidosis field or look for new treatment regimens for themselves. Come with your questions!

Schedule & Agenda

The panelist Audrey Burton-Bethke
01:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Heather Landau.
The panelist Dr. Heather Landau
01:05 PM
Presentation
Dr. Heather Landau
Dr. Heather Landau shares potential clinical trials for amyloidosis patients.
Event panelist Audience
01:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Dr. Heather Landau
Dr. Heather Landau

I am a board-certified oncologist and hematologist, and work as part of a multidisciplinary team caring for patients with hematologic disorders. I have a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis. My research focuses on new treatment approaches for plasma cell disorders. Along with colleagues here, I am testing targeted therapies, immunomodulatory agents, and stem cell transplantation to arrive at more-effective and less-toxic regimens for these diseases. Very effective novel agents have recently become available for plasma cell disorders, but it is not clear if these are more effective than stem cell transplantation for patients early in the course of their disease. To help answer that question, I am co-leading a study comparing the effectiveness of an immunomodulatory agent (lenalidomide) with that of high-dose therapy and stem cell transplantation. I am also leading a trial to determine the most effective post-stem cell transplant therapy. As the principal investigator of an ongoing trial using a risk-adapted approach to stem cell transplant followed by novel agents in AL amyloidosis, I have had the opportunity to present exciting results demonstrating significant activity and low toxicity with this approach. For patients whose plasma cell disorder has relapsed, I am investigating novel agents alone and in combinations. Some patients with multiple myeloma and plasma cell disorders do poorly despite treatment. I am collaborating with colleagues here in efforts to develop safer and more-effective donor-derived (allogeneic) hematopoietic stem cell transplantation options using T-cell-depleted grafts, a strategy pioneered at Memorial Sloan Kettering. In order to improve accessibility to treatment and the quality of life of our patients, I am also helping to develop outpatient transplant strategies using state-of-the-art technology (Tele-Health monitoring). I have also enjoyed mentoring students from the college level through the post-graduate level.

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the AL Amyloidosis group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.